Pediatric brain tumors are the most common solid tumors in children, with various manifestations depending on the classification, grading, size, and location of the brain tumor. Clinical symptoms are extremely diverse, and treatment strategies usually require a combination of surgical resection, radiation therapy, and chemotherapy. The effectiveness of the overall treatment is influenced by various factors such as the monitoring of children's neurocognitive function, assessment of endocrine function, and nutritional intake post-surgery. These elements of care require a collaborative approach across different specialties and stages of treatment. In Taiwan, about 100-120 cases of pediatric brain tumors occur annually, which are scattered among various hospitals and specialties, or referrals to specific medical centers for consultation and follow up. The different locations make it extremely difficult for patients and their families to commute between hospitals for a lengthy period of time.

As early as 2010-2013, the Ministry of Health and Welfare launched the Cancer Excellence Research Program System to promote interdisciplinary and integrated cancer research on brain tumors. The aim was to establish uniform diagnostic criteria and treatment approaches, and also to develop innovative and translational methods for early prevention, diagnosis, and treatment of cancer.

Professor Tai-Tong Wong from Taipei Veterans General Hospital coordinated the "Cancer Excellence Research Program-Annual Symposium on Pediatric Brain Tumors," held at the end of every year. The symposium brings together scholars from both domestic and foreign institutions, including Professor Eric Bouffet, Michael Taylor, Annie Huang, Cynthia Hawkins, and James Rutka from the Hospital for Sick Children in Toronto, Canada; Professor Claire Alapetite from France; Professor James Nicholson from the UK; Professor Jonathan Finlay and Stephen Sands from the United States; and Professor Masao Matsutani and Koichi Ichimura from Japan. The scholars engage in detailed discussions and updates regarding the diagnosis and treatment approaches for different categories of tumors, including childhood germ cell tumors, medulloblastoma, atypical teratoid/rhabdoid tumors, astrocytomas, and ependymomas. Engaging speeches were delivered regarding cutting-edge bioinformatics platforms utilized to identify biomarkers in brain tumors, and latest global advancements allows us to witness the rapid progress of biomedical science, which has become increasingly important for aiding clinical practices.

Since 2014, the Ministry of Health and Welfare has integrated clinical treatments and molecular diagnosis programs for pediatric cancer in Taiwan. Professor Alice Lin-Tsing Yu led the integration of pediatric cancer teams from medical centers across Taiwan during the first phase in 2014-2015 and the second phase in 2016-2017. To support the program, Professor Tai-Tong Wong established the Pediatric Brain Tumor Consortium. The first preparatory meeting was held in August 2016, and during the second preparatory meeting in November, professional groups were established, including radiation oncology, neurological rehabilitation, neuropathology, neuro-oncology, neuroendocrinology, pediatric neurology, neuroimaging diagnosis, pediatric neurosurgery, biobank, genomic research, biostatistics, Taiwan Pediatric Brain Tumor Consortium clinical and brain tumor genomic integration information platform, Pediatric Cancer Foundation, and Taiwan Children's Cancer Research Group. The data from these groups were integrated and developed into an online prototype.

In January 2017, the preparatory meeting held at the NTU Jingfu Auditorium, Professor Hsien-Tang Chou chaired a meeting with domestic neuro-oncology experts to develop molecular classification, risk levels, and treatment guidelines for medulloblastoma under the framework of the Taiwan Pediatric Cancer Research Group.

Under the third phase of the Pediatric Cancer Research Project from 2018-2019, the Pediatric Brain Tumor Consortium was officially established on May 18, 2019, during a preparatory meeting held at Taipei Medical University. Professor Tai-Tong Wong served as the chairman and recruited initiators while applying for administrative procedures from the Ministry of Interior.

The establishment of the Pediatric Brain Tumor Consortium took more than ten years of inter-hospital cooperation and communication. After approval by the Ministry of Interior, a founding member meeting was held on May 23, 2020, with 31 experts from various fields participating. On October 18, 2020, a founding conference was held at the National Taiwan University's Jingfu Hall, attended by over 70 experts from various fields. The organizational charter was passed, and an 11-member board of directors, 3 supervisors, and 5 honorary advisors were established. Professor Tai-Tong Wong was elected as the first chairman of the board. The organization is dedicated to enhancing the quality of medical care for children suffering from brain tumors in Taiwan, fostering the growth of translational medical research, nurturing skilled professionals, and facilitating international collaborations. Its unwavering commitment to fulfilling its obligations of service, education, and research, and pursuing long-term objectives, is evident.